CymaBay (CBAY) Setback a Positive for Intercept Pharmaceuticals (ICPT) - RBC
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $143.00 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) after CymaBay ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
